V. O. Stepanova

V. O. Stepanova

Auto-generated profile, based on publicly available information

V. O. Stepanova

Moscow Regional Oncological Dispensary

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2026 in Bone and soft tissue sarcomas, tumors of the skin
Verified
Journal Article
Open access
PDF file
SGSergey Olegovich Gunyakov
Sergey Olegovich Gunyakov
EIE. V. Inyushkina
E. V. Inyushkina
AKA. V. Khizhnikov
A. V. Khizhnikov
VSV. O. Stepanova
V. O. Stepanova
MRMaxim Yu. Rykov
Maxim Yu. Rykov
Introduction. Epithelioid sarcoma is a rare malignant tumor of the soft tissues developing mostly in young adults. In children this pathology is diagnosed very rarely which often leads to its late verification and unplanned surgical interventions aimed at tumor resection which at early stages is mistaken for a benign neoplasm. The main difficulties are associated with non-specificity of the clinical presentation and the necessity of using immunohistochemical and molecular methods for establishment of the final diagnosis. The article describes a clinical case of diagnosis and treatment of epithelioid soft tissue sarcoma in a child; difficulties of diagnosis associated with morphological verification and differential diagnosis of this tumor are presented, and efficacy of combination treatment consisting of radical surgical intervention and adjuvant radiotherapy is analyzed. Clinical case. A boy, 11 years old, with epithelioid sarcoma of the soft tissues of the right shoulder. For diagnosis, medical history, clinical examination and instrumental methods – ultrasound, magnetic resonance tomography and computed tomography of the thoracic cage and abdomen, scintigraphy and positron emission tomography/computed tomography were used. Additionally, bone marrow biopsy to exclude systemic tumor advancement was performed. Treatment included radical surgical tumor resection with defect reconstruction and subsequent adjuvant radiotherapy at the tumor bed. Efficacy of the therapy was evaluated based on clinical data and results of dynamics in control examinations. No serious complications were reported, local control was achieved, as well as good quality of life of the child in short-term observation period. Conclusion. The presented clinical case demonstrates difficulties of early diagnosis of epithelioid sarcoma in children, adds to the current clinical base, and has practical value for improvement of management of patients of pediatric age with rare tumors of the soft tissues.

1 April 2026 in Clinical oncohematology
Verified
Journal Article
Open access
EIE. V. Inyushkina
E. V. Inyushkina
SGSergey Olegovich Gunyakov
Sergey Olegovich Gunyakov
ABA. V. Bogucharskii
A. V. Bogucharskii
VSV. O. Stepanova
V. O. Stepanova
AIM. To assess the therapy outcomes in pediatric patients with acute myeloid leukemias (AMLs) as well as to identify the most important poor prognostic factors and predictors of treatment efficacy. MATERIALS & METHODS. The retrospective analysis includes 35 newly diagnosed AML patients treated at the Moscow Regional Oncology Dispensary from 2018 to 2025. On diagnosis date, the age range was 0 to 17 years (median 7 years). Therapy (standardized induction and consolidation blocks, targeted drugs if needed, and allogeneic hematopoietic stem cell transplantation [allo-HSCT] in first remission) was administered in accordance with risk groups and obligatory monitoring of minimal residual disease (MRD). Clinical and laboratory features, cytogenetic and molecular markers (FLT3-ITD, NPM1, and CEBPA) as well as MRD were assessed after 1–2 courses of induction therapy. The distribution of FAB types was as follows: M7 in 6 (17.1 %), M1 in 5 (14.3 %), M4 in 5 (14.3 %), M5 in 4 (11.4 %), M5a in 4 (11.4 %), and M2 in 4 (11.4 %) cases; other types were detected in 7 (20 %) cases in total. Risk stratification identified 20 (57.1 %) high-, 12 (34.3 %) intermediate-, and 3 (8.6 %) standard-risk patients. RESULTS. At the time of this publication, 21 (60 %) patients are alive, and 14 (40 %) patients have died. The 3-year overall survival was 60 %, and event-free survival (EFS) was 41 %. In the studied cohort of AML patients, early MRD-negative status appeared to be the main predictor of favorable outcome: with MRD ≥ 0.1 % as early as after the first control examination (25.7 % of patients), the number of events significantly increased and long-term rates decreased, whereas achieving MRD-negative status at the end points went hand in hand with the formation of a pronounced plateau on the EFS curve. Clinical and cytogenetic high-risk parameters (FLT3-ITD mutation, hyperleukocytosis at the start, and extramedullary lesions) were associated with earlier unfavorable outcomes and required treatment escalation. The strategy of incorporating allo-HSCT into first-line therapy proved to have outstanding clinical efficacy for high-risk patients and those with MRD persistence. CONCLUSION. The results obtained are consistent with multi-center data on pediatric protocols of AML treatment. This study demonstrated that the risk-adapted therapy taking into account molecular genetic features of the tumor clone as well as MRD monitoring with the routing of patients to allo-HSCT if needed in first complete remission improve long-term survival rates in pediatric AML patients.